Passier Robert, Mummery Christine
Hubrecht Laboratory and Interuniversity Cardiology Institute of the Netherlands, Uppsalalaan 8, 3584 CT Utrecht, The Netherlands.
Curr Opin Biotechnol. 2005 Oct;16(5):498-502. doi: 10.1016/j.copbio.2005.08.003.
In recent years multiple reports indicating that embryonic as well as adult stem cells can differentiate to cardiomyocytes have ignited discussions on whether these stem cells could lead to new therapies for patients with heart disease. Recent developments have been made in the generation of cardiomyocytes from both embryonic and adult stem cells, and progress towards clinical applications in patients with heart failure has been made. Nevertheless, controversies surrounding safety and transdifferentiation issues will need to be overcome before these stem cell approaches can reach their full potential.
近年来,多项报告表明胚胎干细胞和成体干细胞均可分化为心肌细胞,这引发了关于这些干细胞能否为心脏病患者带来新疗法的讨论。从胚胎干细胞和成体干细胞生成心肌细胞方面已有新进展,并且在心力衰竭患者的临床应用上也取得了进步。然而,在这些干细胞方法充分发挥其潜力之前,围绕安全性和转分化问题的争议仍需克服。